Cargando…
A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes
LY2881835 is a selective, potent, and efficacious GPR40 agonist. The objective of the studies described here was to examine the pharmacological properties of LY2881835 in preclinical models of T2D. Significant increases in insulin secretion were detected when LY2881835 was tested in primary islets f...
Autores principales: | Chen, Yanyun, Song, Min, Riley, Jonathan P., Hu, Charlie C., Peng, Xianbu, Scheuner, Donalyn, Bokvist, Krister, Maiti, Pranab, Kahl, Steven D., Montrose‐Rafizadeh, Chahrzad, Hamdouchi, Chafiq, Miller, Anne Reifel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226292/ https://www.ncbi.nlm.nih.gov/pubmed/28097011 http://dx.doi.org/10.1002/prp2.278 |
Ejemplares similares
-
Structural basis for GPR40 allosteric agonism and incretin stimulation
por: Ho, Joseph D., et al.
Publicado: (2018) -
Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice
por: Nakamoto, Kazuo, et al.
Publicado: (2017) -
EPA Prevents the Development of Abdominal Aortic Aneurysms through Gpr-120/Ffar-4
por: Kamata, Ryo, et al.
Publicado: (2016) -
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
por: Lückmann, Michael, et al.
Publicado: (2019) -
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
por: Bazydlo-Guzenda, Katarzyna, et al.
Publicado: (2021)